CD4 and neoplasm: These data indicate that a higher frequency of total immune cell infiltration, as well as increased specific effector CD4+ and CD8+ T cell subsets, with a concomitant decrease in suppressive myeloid cells in the tumour microenvironment, correlate with clinical response to this regimen in the neoadjuvant setting.